Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sanofi Pasteur, the vaccines division of sanofi-aventis Group, has signed an exclusive collaboration and commercialization agreement with Crucell for Crucell's rabies monoclonal antibodies, next-generation rabies biologicals to be used in association with rabies vaccine for post-exposure prophylaxis.
Subscribe to our email newsletter
Under the terms of the agreement, Crucell will continue to perform the development activities and will manufacture the final product. Crucell will receive a payment of E10 million following the execution of the agreement and would be eligible for milestone payments of up to E66.5 million.
Crucell has developed a combination of two rabies monoclonal antibodies (MAbs) that has shown favorable results comparable to current immunoglobulin products in preclinical trials. Phase I clinical trials demonstrated that the MAb-based product is well tolerated, provides the expected immediate passive neutralizing activity, and that it can be safely administered in combination with a rabies vaccine without interfering with the vaccine’s ability to induce an active immunity.
Wayne Pisano, president and CEO of Sanofi Pasteur, said: “Adding a next generation rabies treatment to our well-established rabies product range will further position the company as a leading force to help prevent this fatal disease.”